The HCP places a new prescription for octreotide for a client. Which indication would the nurse note in the medical record prior to administering the medication? Select all that apply

Rationale: A. Fluid overload related to increased ADH: Octreotide is not used to treat Syndrome of Inappropriate Antidiuretic Hormone (SIADH). In fact, octreotide can sometimes interfere with water excretion, which would not be helpful in a fluid overload state. Treatments for SIADH usually include fluid restriction or medications like vaptans (tolvaptan). B. Acute GI bleed related to esophageal varices: Octreotide causes splanchnic vasoconstriction, which reduces portal venous pressure and decreases blood flow to esophageal varices. This makes it an effective intervention to control acute bleeding from varices in clients with portal hypertension, commonly seen in liver disease. C. Diabetes insipidus after a traumatic brain injury: Diabetes insipidus involves ADH deficiency, leading to excessive urination and hypernatremia. Octreotide does not replace ADH and would not be used to treat this condition; in fact, it could worsen polyuria by inhibiting hormone release. D. Carcinoid tumor of the bowel: Octreotide inhibits the secretion of serotonin and other vasoactive substances from carcinoid tumors, reducing symptoms such as flushing and diarrhea. It is commonly prescribed for symptom management in clients with carcinoid syndrome. E. Height and weight are below the normal expected findings: While octreotide can affect growth hormone secretion, its primary indication is not to manage growth deficiency. Monitoring growth parameters may be relevant in pediatric endocrine disorders, but low height and weight alone are not a direct indication for octreotide therapy.